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Abstract
d-Amino acids have been known to be present in bacteria for more than 50 years, but only recently they were identiﬁed in mammals.
The occurrence of d-amino acids in mammals challenge classic concepts in biology in which only l-amino acids would be present or
thought to play important roles. Recent discoveries uncovered a role of endogenous d-serine as a putative glial-derived transmitter that
regulates glutamatergic neurotransmission in mammalian brain. Free d-serine levels in the brain are about one third of l-serine values
and its extracellular concentration is higher than many common l-amino acids. d-Serine occurs in protoplasmic astrocytes, a class of glial
cells that ensheath the synapses and modulate neuronal activity. Biochemical and electrophysiological studies suggest that endogenous
d-serine is a physiological modulator at the co-agonist site of NMDA-type of glutamate receptors. We previously showed that d-serine
is synthesized by a glial serine racemase, a novel enzyme converting l-t od-serine in mammalian brain. The enzyme requires pyridoxal
5 -phosphate and it was the ﬁrst racemase to be cloned from eucaryotes. Inhibitors of serine racemase have therapeutic implications for
pathological processes in which over-stimulation of NMDA receptors takes place, such as stroke and neurodegenerative diseases. Here, we
review the role of endogenous d-serine in modulating NMDA neurotransmission, its biosynthetic apparatus and the potential usefulness
of serine racemase inhibitors as a novel neuroprotective strategy to decrease glutamate/NMDA excitotoxicity.
© 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
d-Aminoacidsaremirror,looking-glassimagesoftheirl-
counterparts. Though their chemical properties are identical,
they play distinct roles in living organisms. In most bacteria,
d-amino acids are components of the cell wall peptidogli-
can, making them more resistant to glycopeptide antibiotics
(Roper et al., 2000). Despite a few reports of d-amino acids
in invertebrates, it took ﬁve decades to begin uncovering
the roles of d-amino acids in mammals. The neurobiology
of such odd chiral molecules reveals new mechanisms to
modulate neurotransmission and also established the con-
servation of d-amino acid metabolism in mammals. Lajtha
and coworkers ﬁrst detected the presence of high levels of
free d-aspartate in the rat and human brain (Dunlop et al.,
1986). Subsequently, Hashimoto et al. discovered remark-
able quantities of d-serine in mammalian brain at levels even
higher than some l-amino acids (Hashimoto et al., 1992).
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d-Aspartate occurs in neurons in the early stages of the de-
velopment (Wolosker et al., 2000) and is enriched in neu-
roendocrine tissues in the adulthood (Schell et al., 1997a).
By contrast, high densities of d-serine are found in astroglial
cells in gray matter areas of the brain (Schell et al., 1995); its
levels in neurons are much lower, barely detectable with spe-
cialimmunohistochemicaltechniques(Yasudaetal.,2001a).
In the past few years, several roles for d-amino acids in
mammals have been proposed. For instance, d-aspartate ac-
cumulates over time in PC12 cell cultures (Long et al., 1998)
and is synthesized from l-aspartate in primary neuronal cul-
tures (Wolosker et al., 2000). d-Aspartate was shown to in-
ﬂuence the secretion of several hormones, such as growth
and luteinizing hormones, testosterone, melatonin and oxy-
tocin (D’Aniello et al., 1996; Ishio et al., 1998; Nagata
et al., 1999; D’Aniello et al., 2000; Wang et al., 2000).
Pharmacological studies have shown that d-serine activates
NMDA receptor responses by binding to the “glycine site”
of the receptor with identical or even higher afﬁnity than
the co-agonist glycine (Danysz et al., 1990; Matsui et al.,
1995; Danysz and Parsons, 1998). This led Hashimoto and
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co-workers to propose that d-serine would be an endogenous
agonist of NMDA receptors (Hashimoto et al., 1993a). Sub-
sequently, immunohistochemical experiments demonstrated
that d-serine is enriched in astrocytes in regions contain-
ing highest levels of NMDA receptors (Schell et al., 1995).
Direct evidence that endogenous d-serine regulates NMDA
receptors came from experiments in which NMDA receptor
activity in slices and cell cultures diminished after the se-
lective removal of endogenous d-serine by adding d-amino
acidoxidase,anenzymethatdestroysd-serine(Mothetetal.,
2000). Release of d-serine from astrocytes to regulate post-
synaptic NMDA receptors represents a new form of glial-
neuronal communication to modulate neurotransmission.
Becauseenzymesthatconvertl-tod-aminoacids,namely
racemases, were though to be restricted to bacteria, the pres-
ence of d-serine in the brain was regarded by many as of
exogenous origin, derived either from the diet or by the
activity of intestinal bacteria. Recently, mammalian serine
racemases have been puriﬁed and cloned from mouse and
human brain (Wolosker et al., 1999a,b; De Miranda et al.,
2000). Pharmacological inhibition of serine racemase de-
creases cellular d-serine levels and provides a new strategy
to decrease NMDA receptor coactivation (Panizzutti et al.,
2001). Additionally, several aspects of the neurobiology of
d-serine can be learned from the cloned enzyme and are also
subject of our present review.
2. D-Serine disposition
d-Serine occurs almost exclusively in the mammalian
brain with much lower levels in peripheric tissues
(Hashimoto et al., 1992, 1993a). Highest levels of d-serine
were observed in forebrain areas, such as cerebral cor-
tex, hippocampus and striatum (Hashimoto et al., 1993a).
d-Serine levels in the brain are about two orders of mag-
nitude higher than d-alanine, which is the most prevalent
neutral d-enantiomer in bacteria. In the extracellular ﬂuid,
d-serine concentration ranges from 5 to 7M in fore-
brain areas, three- to ﬁve-fold higher than l-glutamate
and l-aspartate as measured by in vivo microdialysis
(Hashimoto et al., 1995).
To determine its cellular localization and assess its candi-
dacy as a neuromodulator, Schell et al. developed a stereos-
elective antibody against d-serine and localized d-serine to
protoplasmic astrocytes in the gray matter, with a distribu-
tion closely resembling that of NR2A/B subtypes of NMDA
receptors (Schell et al., 1995, 1997b). d-Serine densities are
inversely correlated with the expression of d-amino acid
oxidase, an enzyme that robustly deaminates neutral d-( b u t
not l-) amino acids (Schell et al., 1995). d-Amino acid
oxidase was discovered more than six decades ago (Krebs,
1935), but the full appreciation of its function was hampered
by the lack of knowledge on the existence of d-enantiomers
in mammals, especially in the brain. Hence, the inverse
localizations of d-serine and d-amino acid oxidase implies
that the enzyme play a role in metabolizing endogenous
d-serine. In the developing cerebellum, Bergmann glia
stains intensely for d-serine and has no detectable d-amino
acid oxidase (Schell et al., 1995). Animals older than 3
weeks begin to express d-amino acid oxidase in the cere-
bellum (Horiike et al., 1987), which coincides with a large
reduction of d-serine levels in Bergmann glia (Schell et al.,
1997b). Accordingly, mice expressing an inactive mutant
form of d-amino acid oxidase exhibit a 10-fold increase
of d-serine levels in the cerebellum and in the brainstem,
indicating that d-amino acid oxidase is the catabolic en-
zyme for d-serine in those regions (Hashimoto et al.,
1993b).
3. D-Serine as an endogenous agonist of
NMDA receptors
NMDA-type of glutamate receptors are a class of
ionotropic receptor channels that require binding of more
than one agonist to mediate ion inﬂux, i.e. the channel
only functions if both a glutamate site and co-agonist
site are occupied. From the pioneering work of Ascher
and others, it was thought that glycine was the sole
co-agonist that physiologically activates NMDA receptors
(Johnson and Ascher, 1987; Kleckner and Dingledine,
1988). Glycine binding to NMDA receptor is insensitive to
strychnine and this co-agonist site is generally referred to
as strychnine-insensitive site. Though the concentrations of
glycine required to fully activate NMDA receptors are in
the submicromolar range, the synaptic glycine levels un-
dergo dynamic regulation by a powerful glycine reuptake
system and abundant evidence has been accumulated that
this site is not saturated in vivo (Bergeron et al., 1998; for
review see also Danysz and Parsons, 1998). Moreover, the
studies demonstrating the requirement of a co-agonist to
activate NMDA receptor did not address the identity of the
endogenous co-agonist, but rather showed that exogenous
applied glycine was sufﬁcient to fully activate NMDA re-
ceptor activity (Johnson and Ascher, 1987; Kleckner and
Dingledine, 1988).
Several lines of evidence indicate that d-serine is an
endogenous ligand of the NMDA receptor. d-Serine is up
to three-fold more potent than glycine at the co-agonist
site of NMDA receptors (Matsui et al., 1995). Extracellu-
lar d-serine concentration is similar or even higher than
glycine in some brain areas as measured by in vivo mi-
crodialysis (Hashimoto et al., 1995). d-Serine localizes
to gray matter areas enriched in NMDA receptors, while
glycine densities are prominent in the brainstem and spinal
cord (Schell et al., 1997b). Moreover, d-serine is function-
ally 100 times more effective than glycine in potentiating
NMDA receptor-mediated spontaneous synaptic currents in
hypoglossal motoneurons (Berger et al., 1998). The differ-
ence between the relative activities of exogenous d-serine
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receptors has been attributed to the presence at synapses
of a glycine transporter that sets the cleft concentration of
glycine well below that required to saturate the glycine site
(Berger et al., 1998; Bergeron et al., 1998).
To directly assess the identity of the endogenous
co-agonist, Mothet et al. (2000) employed a simple strategy
to selectively deplete brain slices and cell cultures from
endogenous d-serine. They pre-incubated slices and cell
cultures with the enzyme d-amino acid oxidase, which de-
stroyed more than 90% of total d-serine content without
affecting other amino acid levels. d-Amino acid oxidase se-
lectively decreased NMDA receptor responses by 50–70%.
In hippocampal cell cultures, d-amino acid oxidase reduced
the amplitude of spontaneous NMDA receptor-mediated
synaptic currents with no effect on the frequency, imply-
ing a post-synaptic effect. The inhibitory effect of d-amino
acid oxidase was fully reversed by exogenous d-serine.
Non-NMDA ionotropic excitatory amino acid receptor
function was unaffected by the enzyme. Thus, in the context
of previous studies showing that d-serine is a potent agonist
ligand for the strychnine-insensitive glycine site of NMDA
receptors (Matsui et al., 1995; Danysz and Parsons, 1998),
thedatastronglysupportaroleford-serineasanendogenous
co-agonistofNMDAreceptors(Mothetetal.,2000).NMDA
responses were not fully blocked by addition of d-amino
acid oxidase. The d-amino acid oxidase-insensitive varied
depending on the experimental conditions, ranging from 30
to 50% of NMDA activity. Thus, endogenous glycine might
account for activation of the remaining co-agonist sites of
the NMDA receptor and may be the main endogenous ligand
in other parts of the brain, such as brainstem and spinal cord.
Even in the spinal cord, in which glycine concentration
is higher than in the forebrain, d-serine may also be an en-
dogenous ligand of the NMDA receptor. Accordingly, mice
expressing an inactive mutant form of d-amino acid oxidase
along with augmented d-serine levels in the spinal cord ex-
hibited an increase on NMDA receptor-mediated excitatory
post-synaptic currents recorded from dorsal horn neurons
(Wake et al., 2001).
At present, the synaptic concentration of d-serine and
glycine are not known. Selective blockers of d-serine up-
take system or biosynthetic apparatus should allow the dis-
tinction of glutamatergic synapses that are pre-dominantly
dependent on d-serine from those modulated by glycine.
4. Serine racemase
The high levels of d-serine in discrete areas of rat brain
imply the existence of a biosynthetic pathway. We felt
that l-serine was a strong candidate to serve as precursor
for d-serine synthesis. Intraperitoneal injection of l-serine
promoted accumulation of d-serine in the cerebral cortex
(Takahashi et al., 1997) and injection of [3H] l-serine into
rat brain led to accumulation of labeled d-serine as well
(Dunlop and Neidle, 1997). Both l-serine and d-serine are
enriched in astrocytes, which possess the enzymatic appa-
ratus to synthesize l-serine (Yamasaki et al., 2001; Yasuda
et al., 2001b).
To purify serine racemase, we added l-serine to brain
subfractions and measured the conversion of l-t od-serine
(Wolosker et al., 1999a). Like bacterial racemases, the puri-
ﬁed mammalian serine racemase requires the cofactor pyri-
doxal 5 -phosphate (Wolosker et al., 1999a). The enzyme is
highly selective toward l-serine, failing to racemize other
aminoacids(Woloskeretal.,1999a).Theclonedenzymehas
30–40% homology to enzymes of the serine/threonine dehy-
dratase family, which like serine racemase, are dependent on
pyridoxal 5 -phosphate (Wolosker et al., 1999b; De Miranda
et al., 2000). Though several amino acid racemases have
been cloned from bacterial sources, no eukaryotic amino
acid racemase has been previously cloned. All of the known
amino acid racemases have been cloned from archae or eu-
bacteria including alanine, aspartate, glutamate, serine and
phenylalanine racemase. However, none of these display
signiﬁcant amino acid sequence homology to serine race-
mase, implying that the mammalian racemase evolved from
an ancestor related to the serine/threonine dehydratase fam-
ily. Over-expression of serine racemase in cultured HEK293
cells elicits robust synthesis of d-serine and the amounts
of d-serine produced greatly increase as l-serine is supple-
mented to the culture media (Wolosker et al., 1999b). Serine
racemase is highly enriched in brain and localizes to astro-
cytes with a distribution pattern similar to that of d-serine.
Co-localization of serine racemase and d-serine in glia in-
dicates that d-serine is formed in the cells that contain en-
dogenous d-serine rather than being synthesized in neurons
and transported into glia.
Since d-serine is an endogenous agonist of NMDA re-
ceptors, selective inhibitors of serine racemase should be
valuable tools for investigating the regulation of NMDA
transmission. Moreover, serine racemase can also be con-
ceived as a novel therapeutic target. Massive stimulation
of NMDA receptors is implicated in neural damage fol-
lowing stroke (Choi and Rothman, 1990) and inhibitors of
serine racemase may be useful to prevent stroke damage.
Elevations of extracellular concentrations of d-serine are
observed after transient cerebral ischemia in rats (Lo et al.,
1998). Drugs that block the “glycine site” of NMDA recep-
tors prevent stroke damage in animal models (Gill et al.,
1995), but were not well tolerated in clinical trials or did
not attained therapeutic levels in the brain due to poor pen-
etration into the blood-brain barrier (Danysz and Parsons,
1998). Thus, inhibitors of serine racemase provide a new
strategy to decrease NMDA receptor coactivation and may
be useful in conditions such as stroke and neurodegenerative
diseases where over-stimulation of NMDA receptors play
a pathological role (Panizzutti et al., 2001). We recently
demonstrated that serine racemase activity and d-serine syn-
thesis in primary astrocyte cultures is inhibited by l-serine
O-sulphate, which is a model compound for designing
selective activity-based inhibitors (Panizzutti et al., 2001).330 H. Wolosker et al./Neurochemistry International 41 (2002) 327–332
The study of serine racemase properties and regulation
will be important to learn the mechanism by which this
unusual enzyme works and also will further shed light on
the neurobiology of d-serine.
5. D-Serine and schizophrenia
NMDA receptor hypofunction has been implicated in the
pathophysiology of schizophrenia. NMDA antagonists, such
as phencyclidine, induce positive, negative, and cognitive
schizophrenic-like symptoms in healthy volunteers and pre-
cipitate thought disorder and delusions in schizophrenia pa-
tients (Goff and Coyle, 2001). Animal studies also support
this hypothesis. Mice expressing only 5% of normal lev-
els of NMDAR1 (NR1) subunit display behavioral abnor-
malities, including increased motor activity and stereotypy
and deﬁcits in social and sexual interactions (Mohn et al.,
1999). As a selective agonist of NMDA receptor, d-serine
reverses the hyperactivity and stereotype behavior induced
by NMDA receptors antagonists (Contreras, 1990).
Based on the NMDA receptor hypofunction hypothesis,
several clinical trials were carried out to evaluate the efﬁcacy
of map co-agonists of NMDA receptors in schizophrenic
patients. Glycine administration was shown to greatly im-
prove symptoms of schizophrenia (Heresco-Levy et al.,
1996, 1999). Likewise, in a study conducted by Coyle and
associates, d-serine greatly improved the positive, negative,
and cognitive symptoms of schizophrenic subjects when as-
sociated to conventional neuroleptics (Tsai et al., 1998). The
beneﬁcial effect of d-serine as adjuvant therapy supports
Fig. 1. d-serine: a putative glial-derived transmitter. d-Serine is synthesized from l-serine in astrocytes (AST) by serine racemase. l-Glutamate (l-Glu)
released from neurons interacts with kainate-type of glutamate receptors in astrocytes (Ast) to stimulate the release of d-serine. d-Serine acts in concert
with glutamate to activate post-synaptic NMDA receptors.
the NMDA hypofunction hypothesis for schizophrenia, but
the efﬁcacy of the therapy should be further conﬁrmed in
additional clinical trials.
6. A putative glial-derived transmitter
In recently years, it has been shown that astrocytes and
neurons exhibit a dynamic signaling that profoundly inﬂu-
ences neuronal activity and development (Haydon, 2001;
Lemke, 2001). It has been shown that astrocytes directly
increase neuronal transmission by releasing chemical trans-
mitters, such as glutamate (Haydon, 2001). Moreover, astro-
cytes undergo spontaneous calcium oscillations that trigger
NMDA receptor-mediated inward currents in neurons (Parri
et al., 2001). Within this context, we propose that d-serine
is a new type of transmitter released from glia to inﬂuence
nearby neurons (Fig. 1). We have previously shown that
d-serine is synthesized by a speciﬁc racemase located in
glia (Wolosker et al., 1999a,b). d-Serine accumulated in as-
trocytes cultures is released by kainate, a potent agonist of
non-NMDA receptors enriched in glia (Schell et al., 1995).
Upon release, d-serine acts on a speciﬁc target, the NMDA
receptor in nearby neurons (Fig. 1). The concerted action of
glutamate and d-serine would be required for full NMDA
receptor activation. Thus, d-serine seems to play a role in a
new type of glial-neuronal communication.
To clarify the role of d-serine as a modulator of NMDA
receptors, one should identify the factors that will promote
the termination of d-serine signaling. Though d-amino acid
oxidase levels are high in the cerebellum and brainstem,H. Wolosker et al./Neurochemistry International 41 (2002) 327–332 331
previous studies failed to detect signiﬁcant amounts of
d-amino acid oxidase in the forebrain (Horiike et al., 1987).
Thus, it is conceivable that d-serine could be removed from
the synaptic cleft by amino acid transporters. A d-serine
uptake was demonstrated in C6 glioma cells, with proper-
ties resembling ASCT2 neutral amino acid transport system
(Hayashietal.,1997).Incorticalastrocytes,wealsodetected
bi-directional transport of d-serine by a similar mechanism
(Ribeiro et al., 2002). Recently, a high-afﬁnity transport
system for d- and l-amino acids has been cloned, but its
presence in astrocytes and localization in the brain have
not been determined yet (Fukasawa et al., 2000). Another
possibility is that the synaptic concentration of d-serine
will be largely regulated by the activity of the biosynthetic
enzyme, serine racemase. If this will be the case, d-serine
signaling properties will resemble other non-conventional
transmitters, such as nitric oxide and carbon monoxide, that
lack speciﬁc degrading systems and their extracellular levels
are regulated mostly by the activities of their biosynthetic
enzymes (Snyder and Ferris, 2000).
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